Bill Lis, Jasper Therapeutics
Jasper and its stem cell conditioning antibody earn a ticket to Nasdaq in latest SPAC reverse merger
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Another biotech SPAC deal has landed as the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
